HCW Biologics (HCWB) Income towards Parent Company (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Income towards Parent Company data on file, last reported at -$4.7 million in Q4 2025.

• Quarterly Income towards Parent Company fell 40.64% year-over-year to -$4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$14.0 million (up 53.35% YoY) and the FY2025 annual result came in at -$40.6 million, up 27.11% from the prior year.
• Income towards Parent Company eased to -$4.7 million in Q4 2025, from -$3.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$1.9 million in Q1 2022 to a low of -$15.3 million in Q2 2024.
• A 5-year average of -$5.2 million and a median of -$4.2 million in 2021 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2021 — Income towards Parent Company tumbled 309.53% — and 2025, when it surged 75.86%.
• Tracing HCWB's Income towards Parent Company over 5 years: stood at -$4.2 million in 2021, then slumped by 35.99% to -$5.8 million in 2022, then sank by 86.87% to -$10.8 million in 2023, then jumped by 69.13% to -$3.3 million in 2024, then sank by 40.64% to -$4.7 million in 2025.
• The last three Income towards Parent Company figures came in at -$4.7 million (Q4 2025), -$3.4 million (Q3 2025), and -$3.7 million (Q2 2025), per Business Quant data.